Freeslate, Inc., a provider of high throughput research solutions for biopharmaceutical development, announced highlights of its Biologics Formulation Summit that was held May 20-21, 2014 in Malvern, Pennsylvania.
"Developing biologic drug products has always been a complex challenge, and today, the demands placed on development organizations are only increasing," said John S. Senaldi, President and CEO of Freeslate. Formulation development labs are under growing pressure to increase productivity due to a number of factors: implementation of Quality by Design (QbD) initiatives requiring a broader understanding of the formulation design space, an increasing number of biologics candidates, and reduced available resources.
The Summit consisted of case-study presentations by a diverse set of customers including Janssen Pharmaceutical, Novo Nordisk, KBI Biopharma, and Amgen.
Additional information about the Biologics Formulation Summit can be found here.